TAK - Takeda gets Japan nod for first post-transplant anti-CMV treatment
2024-06-24 11:58:27 ET
More on Takeda Pharmaceutical
- Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
- Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation
- Takeda gets EU approval for Fruzaqla for colorectal cancer
- Ovid stock plunges 66% on failed studies for soticlestat